SCL Science

SCL Science Debt/EBITDA

The Total Debt to EBITDA Ratio of SCL Science (246960.KQ) as of Oct 17, 2026 is -4.16. In the previous year, Total Debt to EBITDA Ratio was -1.17 — a change of 253.86% (lower).

Debt/EBITDA

-4.16

YoY

253.86%

Last updated:

Total Debt to EBITDA Ratio of SCL Science is 2025 -4.16 . Total Debt to EBITDA Ratio of SCL Science was 2024 -1.17 . It decreases by 253.86% lower compared to the previous year.

The SCL Science Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
-0.32 KRW
Jan 1, 2019
-0.12 KRW
Jan 1, 2020
-0.98 KRW
Jan 1, 2021
-4.12 KRW
Jan 1, 2022
-2.23 KRW
Jan 1, 2023
-1.08 KRW
Jan 1, 2024
-1.17 KRW
Jan 1, 2025
-4.16 KRW
The SCL Science Debt/EBITDA history
YEARDebt/EBITDAYoY
-4.16+253.86%
-1.17+8.91%
-1.08-51.54%
-2.23-45.96%
-4.12+320.78%
-0.98+703.27%
-0.12-62.22%
-0.32+74.91%
-0.18—
0.00-100.00%
-6.78—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Total Debt to EBITDA Ratio of SCL Science is -4.16 in 2025.

Total Debt to EBITDA Ratio of SCL Science changed from -1.17 to -4.16, representing a 253.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio SCL Science since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's SCL Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SCL Science

All Key Metrics — SCL Science